KMT2D is also one of the most frequently mutated genes across a number of neoplasms, including breast cancer, non-Hodgkin's lymphoma (NHL) such as DLBCL and follicular lymphoma, bladder cancer, prostate cancer, colorectal cancer, esophageal squamous cell cancer, T cell lymphoma, and acute myeloid lymphoma (55, 57, 58, 59). This evidence concerns the gene KMT2D and prostate carcinoma.